Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Ovarian Cancer | Research

Relationship between PIWIL1 gene polymorphisms and epithelial ovarian cancer susceptibility among southern Chinese woman: a three-center case–control study

Authors: Shanshan Liu, Yaping Yan, Zhizhong Cui, Haipeng Feng, Fengmei Zhong, Ziguang Liu, Yan Li, Xiang Ou, Wenjuan Li

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Objective

To investigate the potential correlation between piwi-like RNA-mediated gene silencing 1 (PIWIL1) polymorphisms and susceptibility to epithelial ovarian cancer (EOC).

Methods

A case–control study was conducted to evaluate the susceptibility of EOC using multinomial logistic regression analysis. The study analyzed the relationship between five functional single nucleotide polymorphisms (SNPs) in the PIWIL1 gene and EOC risk. Genotyping of 288 cases and 361 healthy samples from South China was identified using a TaqMan assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the relationship between the five selected SNPs and EOC susceptibility.

Results

Among the five SNPs analyzed, the rs10848087 G > A and rs7957349 G > C variants significantly increased the susceptibility of EOC, rs10773771 C > T was associated with a decreased risk of EOC, while the rs35997018 and rs1106042 variants were not in Hardy–Weinberg equilibrium (p < 0.05). The rs10848087 G > A was significantly associated with increased risk of EOC in individuals with metastasis, FIGO stage I and III, low and high pathological grade, tumor numbers ≤ 3 and > 3, tumor size > 3 cm and ≤ 3 cm, pregnant more than 3 times, pre-menopausal status, and strong positive expression of ER (estrogen receptor), PR (progesterone receptor), PAX8 (paired-box 8), wild-type p53 (tumor protein 53), WT1 (Wilm’s tumor gene), P16 (cyclin-dependent kinase inhibitor 2A). In addition, rs10848087 G > A enhanced the EOC risk of cases with negative/mild positive expression of wild p53 and Ki67, and with or without mutant p53 expression. The rs7957349 G > C variant was linked to an increased risk of EOC in subgroups with certain characteristics, including age equal or less than 53 years, metastasis, clinical stage I, low pathological grade, tumor number, tumor size, pregnant times, post-menopause, pre-menopause, and strong positive expression of wild p53 and Ki67 (Antigen identified by monoclonal antibody Ki-67), as well as without mutant p53 expression. The rs10773771 CT/TT alleles were identified to have a protective effect on EOC in women aged 53 years or older, as well as in cases with metastasis, advanced clinical stage, high pathological grade, multiple tumors, tumor size equal to or less than 3 cm, history of pregnancy, post-menopausal status, and strong positive expression of ER, PR, wild-type p53, PAX8, WT1, P16, and Ki67. Furthermore, rs10773771 CT/TT also showed a protective effect in patients with negative or mildly positive expression of PR, PAX8, wild-type p53, WT1, and P16, as well as positive expression of mutant p53. Compared to the reference haplotype GCG, individuals harboring haplotypes GTG were found to have a significantly decreased susceptibility to EOC. PIWIL1 was significantly expressed in the thyroid, pituitary, and adrenal glands with rs7957349 CC alleles.

Conclusions

PIWIL1 rs10848087 and rs7957349 were associated with increased risk of EOC, while rs10773771 may have a protective effect against EOC. These genetic variants may serve as potential biomarkers for EOC susceptibility in the South China population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zheng L, Cui C, Shi O, Lu X, Li YK, Wang W, et al. Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990–2017. Gynecol Oncol. 2020;159(1):239–47.PubMedCrossRef Zheng L, Cui C, Shi O, Lu X, Li YK, Wang W, et al. Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990–2017. Gynecol Oncol. 2020;159(1):239–47.PubMedCrossRef
2.
go back to reference Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022;30(3):349–62.PubMedPubMedCentralCrossRef Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022;30(3):349–62.PubMedPubMedCentralCrossRef
3.
4.
go back to reference Zhao Y-M, Zhou J-M, Wang L-R, He H-W, Wang X-L, Tao Z-H, et al. HIWI is associated with prognosis in patients with hepatocellular carcinoma after curative resection. Cancer Nurs Pract. 2012;118(10):2708–17. Zhao Y-M, Zhou J-M, Wang L-R, He H-W, Wang X-L, Tao Z-H, et al. HIWI is associated with prognosis in patients with hepatocellular carcinoma after curative resection. Cancer Nurs Pract. 2012;118(10):2708–17.
5.
6.
go back to reference Jane HS, M WE, Susan S, Jiemin M, N AR, U FA, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. J Cancer. 2020;126(10):2225–49. Jane HS, M WE, Susan S, Jiemin M, N AR, U FA, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. J Cancer. 2020;126(10):2225–49.
7.
go back to reference Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, et al. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016;7:12645.PubMedPubMedCentralCrossRef Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, et al. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016;7:12645.PubMedPubMedCentralCrossRef
8.
9.
go back to reference Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.PubMedCrossRef Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.PubMedCrossRef
10.
go back to reference Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Can Res. 2003;63(13):3695–700. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Can Res. 2003;63(13):3695–700.
11.
go back to reference Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56.PubMedPubMedCentralCrossRef Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56.PubMedPubMedCentralCrossRef
12.
go back to reference Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, et al. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol. 2017;3(1):76–82.PubMedPubMedCentralCrossRef Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, et al. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol. 2017;3(1):76–82.PubMedPubMedCentralCrossRef
13.
go back to reference Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016;143(1):3–15.PubMedPubMedCentralCrossRef Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016;143(1):3–15.PubMedPubMedCentralCrossRef
14.
go back to reference Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019;37(16):1380–90.PubMedPubMedCentralCrossRef Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019;37(16):1380–90.PubMedPubMedCentralCrossRef
15.
go back to reference Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.PubMedCrossRef Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.PubMedCrossRef
16.
go back to reference Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, et al. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res. 2018;24(4):777–83.PubMedCrossRef Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, et al. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res. 2018;24(4):777–83.PubMedCrossRef
17.
go back to reference Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(11):1222–45.PubMedCrossRef Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(11):1222–45.PubMedCrossRef
18.
go back to reference Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, et al. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncol. 2019;5(12):1718–30.PubMedPubMedCentralCrossRef Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, et al. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncol. 2019;5(12):1718–30.PubMedPubMedCentralCrossRef
19.
go back to reference Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, et al. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. J Clin Oncol. 2019;37(15):1305–15.PubMedPubMedCentralCrossRef Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, et al. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. J Clin Oncol. 2019;37(15):1305–15.PubMedPubMedCentralCrossRef
20.
go back to reference Kurnit KC, Fleming GF, Lengyel E. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2021;137(1):108–21.PubMedCrossRef Kurnit KC, Fleming GF, Lengyel E. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2021;137(1):108–21.PubMedCrossRef
21.
go back to reference Shi S, Yang ZZ, Liu S, Yang F, Lin H. PIWIL1 promotes gastric cancer via a piRNA-independent mechanism. Proc Natl Acad Sci USA. 2020;117(36):22390–401.PubMedPubMedCentralCrossRef Shi S, Yang ZZ, Liu S, Yang F, Lin H. PIWIL1 promotes gastric cancer via a piRNA-independent mechanism. Proc Natl Acad Sci USA. 2020;117(36):22390–401.PubMedPubMedCentralCrossRef
22.
go back to reference Dong L, Zehui F, Min D, Chao L, Chonghao X, Juan Z, et al. Effect of RNA interference-related HiWi gene expression on the proliferation and apoptosis of lung cancer stem cells. J Oncol Lett. 2012;4(1):146–50. Dong L, Zehui F, Min D, Chao L, Chonghao X, Juan Z, et al. Effect of RNA interference-related HiWi gene expression on the proliferation and apoptosis of lung cancer stem cells. J Oncol Lett. 2012;4(1):146–50.
23.
go back to reference FGL, TG, HT, PM, UK, AU, et al. The stem cell-associated Hiwi gene in human adenocarcinoma of the pancreas: expression and risk of tumour-related death. J Br J Cancer. 2008;99(7):1083–8. FGL, TG, HT, PM, UK, AU, et al. The stem cell-associated Hiwi gene in human adenocarcinoma of the pancreas: expression and risk of tumour-related death. J Br J Cancer. 2008;99(7):1083–8.
24.
go back to reference Chen Z, Che Q, Jiang FZ, Wang HH, Wang FY, Liao Y, et al. Piwil1 causes epigenetic alteration of PTEN gene via upregulation of DNA methyltransferase in type I endometrial cancer. Biochem Biophys Res Commun. 2015;463(4):876–80.PubMedCrossRef Chen Z, Che Q, Jiang FZ, Wang HH, Wang FY, Liao Y, et al. Piwil1 causes epigenetic alteration of PTEN gene via upregulation of DNA methyltransferase in type I endometrial cancer. Biochem Biophys Res Commun. 2015;463(4):876–80.PubMedCrossRef
25.
26.
go back to reference Li F, Yuan P, Rao M, Jin CH, Tang W, Rong YF, et al. piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Nat Cell Biol. 2020;22(4):425–38.PubMedCrossRef Li F, Yuan P, Rao M, Jin CH, Tang W, Rong YF, et al. piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Nat Cell Biol. 2020;22(4):425–38.PubMedCrossRef
27.
go back to reference Ye C, Qian W, Wei J, Yonghua B, Yang Z, Anxing G, et al. Emerging roles of piRNAs in cancer: challenges and prospects. J Aging. 2019;11(21):9932–46. Ye C, Qian W, Wei J, Yonghua B, Yang Z, Anxing G, et al. Emerging roles of piRNAs in cancer: challenges and prospects. J Aging. 2019;11(21):9932–46.
28.
go back to reference Wen X, Wang D, Li X, Zhao C, Wang T, Qian X, et al. Differential expression of two Piwil orthologs during embryonic and gonadal development in pufferfish, Takifugu fasciatus. Comp Biochem Physiol B: Biochem Mol Biol. 2018;219–220:44–51.PubMedCrossRef Wen X, Wang D, Li X, Zhao C, Wang T, Qian X, et al. Differential expression of two Piwil orthologs during embryonic and gonadal development in pufferfish, Takifugu fasciatus. Comp Biochem Physiol B: Biochem Mol Biol. 2018;219–220:44–51.PubMedCrossRef
29.
go back to reference Singh G, Roy J, Rout P, Mallick B. Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers. PLoS ONE. 2018;13(1): e0190485.PubMedPubMedCentralCrossRef Singh G, Roy J, Rout P, Mallick B. Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers. PLoS ONE. 2018;13(1): e0190485.PubMedPubMedCentralCrossRef
30.
go back to reference Friemel C, Ammerpohl O, Gutwein J, Schmutzler AG, Caliebe A, Kautza M, et al. Array-based DNA methylation profiling in male infertility reveals allele-specific DNA methylation in PIWIL1 and PIWIL2. Fertil Steril. 2014;101(4):1097-103.e1.PubMedCrossRef Friemel C, Ammerpohl O, Gutwein J, Schmutzler AG, Caliebe A, Kautza M, et al. Array-based DNA methylation profiling in male infertility reveals allele-specific DNA methylation in PIWIL1 and PIWIL2. Fertil Steril. 2014;101(4):1097-103.e1.PubMedCrossRef
31.
go back to reference Zhenzhen L, Lanting Z, Lihong Z, Juan X, Zhengjiang C. Single nucleotide polymorphism of rs28416520 in Piwil1 gene promoter region is associated with an increased risk of gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(10):1373–9.PubMed Zhenzhen L, Lanting Z, Lihong Z, Juan X, Zhengjiang C. Single nucleotide polymorphism of rs28416520 in Piwil1 gene promoter region is associated with an increased risk of gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(10):1373–9.PubMed
32.
go back to reference Cheasley D, Fernandez ML, Köbel M, Kim H, Dawson A, Hoenisch J, et al. Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. NPJ precision oncology. 2022;6(1):47.PubMedPubMedCentralCrossRef Cheasley D, Fernandez ML, Köbel M, Kim H, Dawson A, Hoenisch J, et al. Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. NPJ precision oncology. 2022;6(1):47.PubMedPubMedCentralCrossRef
33.
go back to reference Manu V, Hein TA, Boruah D, Srinivas V. Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis. Med J Armed Forces India. 2020;76(1):30–6.PubMedCrossRef Manu V, Hein TA, Boruah D, Srinivas V. Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis. Med J Armed Forces India. 2020;76(1):30–6.PubMedCrossRef
34.
go back to reference Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Modern Pathol. 2011;24(6):751–64.CrossRef Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Modern Pathol. 2011;24(6):751–64.CrossRef
35.
go back to reference Ozcan A, Liles N, Coffey D, Shen SS, Truong LD. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol. 2011;35(12):1837–47.PubMedCrossRef Ozcan A, Liles N, Coffey D, Shen SS, Truong LD. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol. 2011;35(12):1837–47.PubMedCrossRef
36.
go back to reference Němejcová K, Šafanda A, Bártů MK, Michálková R, Drozenová J, Fabian P, et al. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors. Diagn Pathol. 2023;18(1):32.PubMedPubMedCentralCrossRef Němejcová K, Šafanda A, Bártů MK, Michálková R, Drozenová J, Fabian P, et al. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors. Diagn Pathol. 2023;18(1):32.PubMedPubMedCentralCrossRef
37.
go back to reference McCluggage WG, Singh N, Gilks CB. Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology. 2022;80(5):762–78. McCluggage WG, Singh N, Gilks CB. Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology. 2022;80(5):762–78.
38.
go back to reference Wang X, Deng D, Yan Y, Cai M, Liu X, Luo A, et al. Genetic variants in m5C modification core genes are associated with the risk of Chinese pediatric acute lymphoblastic leukemia: A five-center case-control study. Front Oncol. 2022;12:1082525.PubMedCrossRef Wang X, Deng D, Yan Y, Cai M, Liu X, Luo A, et al. Genetic variants in m5C modification core genes are associated with the risk of Chinese pediatric acute lymphoblastic leukemia: A five-center case-control study. Front Oncol. 2022;12:1082525.PubMedCrossRef
39.
go back to reference Zhang M, Zhao Z, Chen S, Liang Z, Zhu J, Zhao M, et al. The Association of Polymorphisms in Base Excision Repair Genes with Ovarian Cancer Susceptibility in Chinese Women: A Two-Center Case-Control Study. J Cancer. 2021;12(1):264–9.PubMedPubMedCentralCrossRef Zhang M, Zhao Z, Chen S, Liang Z, Zhu J, Zhao M, et al. The Association of Polymorphisms in Base Excision Repair Genes with Ovarian Cancer Susceptibility in Chinese Women: A Two-Center Case-Control Study. J Cancer. 2021;12(1):264–9.PubMedPubMedCentralCrossRef
40.
go back to reference Deng D, Luo A, Li M, Yan Y, Cai M, Liu S, et al. New association between splicing factor-coding gene polymorphisms and the risk of acute lymphoblastic leukemia in southern Chinese children: A five-center case-control study. J Gene Med. 2023;25(4): e3474.PubMedCrossRef Deng D, Luo A, Li M, Yan Y, Cai M, Liu S, et al. New association between splicing factor-coding gene polymorphisms and the risk of acute lymphoblastic leukemia in southern Chinese children: A five-center case-control study. J Gene Med. 2023;25(4): e3474.PubMedCrossRef
41.
go back to reference Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020;22(10):1653–66.PubMedPubMedCentralCrossRef Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020;22(10):1653–66.PubMedPubMedCentralCrossRef
42.
go back to reference Chornokur G, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Amankwah EK, et al. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE. 2015;10(6): e0128106.PubMedPubMedCentralCrossRef Chornokur G, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Amankwah EK, et al. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE. 2015;10(6): e0128106.PubMedPubMedCentralCrossRef
43.
go back to reference Lou D, Wang J, Wang X. Single nucleotide polymorphisms in the non-coding region of STIM1 gene are associated with Parkinson disease risk in Chinese Han population. Medicine. 2020;99(9): e19234.PubMedPubMedCentralCrossRef Lou D, Wang J, Wang X. Single nucleotide polymorphisms in the non-coding region of STIM1 gene are associated with Parkinson disease risk in Chinese Han population. Medicine. 2020;99(9): e19234.PubMedPubMedCentralCrossRef
44.
go back to reference Wang J, Wang X, Zhao M, Choo SP, Ong SJ, Ong SY, et al. Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients. PLoS ONE. 2014;9(11): e111694.PubMedPubMedCentralCrossRef Wang J, Wang X, Zhao M, Choo SP, Ong SJ, Ong SY, et al. Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients. PLoS ONE. 2014;9(11): e111694.PubMedPubMedCentralCrossRef
45.
go back to reference Lim SL, Ricciardelli C, Oehler MK, Tan IM, Russell D, Grützner F. Overexpression of piRNA pathway genes in epithelial ovarian cancer. PLoS ONE. 2014;9(6): e99687.PubMedPubMedCentralCrossRef Lim SL, Ricciardelli C, Oehler MK, Tan IM, Russell D, Grützner F. Overexpression of piRNA pathway genes in epithelial ovarian cancer. PLoS ONE. 2014;9(6): e99687.PubMedPubMedCentralCrossRef
47.
go back to reference Liu L, An J, Liu J, Wen J, Zhai X, Liu Y, et al. Potentially functional genetic variants in microRNA processing genes and risk of HBV-related hepatocellular carcinoma. Mol Carcinog. 2013;52(Suppl 1):E148–54.PubMedCrossRef Liu L, An J, Liu J, Wen J, Zhai X, Liu Y, et al. Potentially functional genetic variants in microRNA processing genes and risk of HBV-related hepatocellular carcinoma. Mol Carcinog. 2013;52(Suppl 1):E148–54.PubMedCrossRef
48.
go back to reference Wang N, Tan HY, Lu Y, Chan YT, Wang D, Guo W, et al. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6(1):86.PubMedPubMedCentralCrossRef Wang N, Tan HY, Lu Y, Chan YT, Wang D, Guo W, et al. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6(1):86.PubMedPubMedCentralCrossRef
49.
go back to reference Xie K, Zhang K, Kong J, Wang C, Gu Y, Liang C, et al. Cancer-testis gene PIWIL1 promotes cell proliferation, migration, and invasion in lung adenocarcinoma. Cancer Med. 2018;7(1):157–66.PubMedCrossRef Xie K, Zhang K, Kong J, Wang C, Gu Y, Liang C, et al. Cancer-testis gene PIWIL1 promotes cell proliferation, migration, and invasion in lung adenocarcinoma. Cancer Med. 2018;7(1):157–66.PubMedCrossRef
50.
go back to reference Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis. 2010;31(10):1805–12.PubMedPubMedCentralCrossRef Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis. 2010;31(10):1805–12.PubMedPubMedCentralCrossRef
51.
go back to reference Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Can Res. 2008;68(7):2530–7.CrossRef Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Can Res. 2008;68(7):2530–7.CrossRef
52.
go back to reference Wang M, Gu J, Shen C, Tang W, Xing X, Zhang Z, et al. Association of MicroRNA Biogenesis Genes Polymorphisms with Risk of Large Artery Atherosclerosis Stroke. Cell Mol Neurobiol. 2022;42(6):1801–7.PubMedCrossRef Wang M, Gu J, Shen C, Tang W, Xing X, Zhang Z, et al. Association of MicroRNA Biogenesis Genes Polymorphisms with Risk of Large Artery Atherosclerosis Stroke. Cell Mol Neurobiol. 2022;42(6):1801–7.PubMedCrossRef
53.
go back to reference Seo J, Byun MS, Yi D, Lee JH, Jeon SY, Shin SA, et al. Genetic associations of in vivo pathology influence Alzheimer’s disease susceptibility. Alzheimers Res Ther. 2020;12(1):156.PubMedPubMedCentralCrossRef Seo J, Byun MS, Yi D, Lee JH, Jeon SY, Shin SA, et al. Genetic associations of in vivo pathology influence Alzheimer’s disease susceptibility. Alzheimers Res Ther. 2020;12(1):156.PubMedPubMedCentralCrossRef
54.
go back to reference Mittica G, Senetta R, Scotto G, Aglietta M, Maggiorotto F, Ghisoni E, et al. Androgen receptor status predicts development of brain metastases in ovarian cancers. Oncotarget. 2017;8(25):41143–53.PubMedPubMedCentralCrossRef Mittica G, Senetta R, Scotto G, Aglietta M, Maggiorotto F, Ghisoni E, et al. Androgen receptor status predicts development of brain metastases in ovarian cancers. Oncotarget. 2017;8(25):41143–53.PubMedPubMedCentralCrossRef
56.
go back to reference Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, et al. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res. 2011;17(3):511–8.PubMedCrossRef Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, et al. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res. 2011;17(3):511–8.PubMedCrossRef
57.
go back to reference Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 2012;12:553.PubMedPubMedCentralCrossRef Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 2012;12:553.PubMedPubMedCentralCrossRef
58.
go back to reference Voutsadakis IA. Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations. Clin Med Insights Oncol. 2016;10:17–25.PubMedPubMedCentralCrossRef Voutsadakis IA. Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations. Clin Med Insights Oncol. 2016;10:17–25.PubMedPubMedCentralCrossRef
59.
go back to reference Latonen L, Laiho M. Cellular UV damage responses–functions of tumor suppressor p53. Biochem Biophys Acta. 2005;1755(2):71–89.PubMed Latonen L, Laiho M. Cellular UV damage responses–functions of tumor suppressor p53. Biochem Biophys Acta. 2005;1755(2):71–89.PubMed
60.
go back to reference Bernardini MQ, Baba T, Lee PS, Barnett JC, Sfakianos GP, Secord AA, et al. Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer. 2010;10:237.PubMedPubMedCentralCrossRef Bernardini MQ, Baba T, Lee PS, Barnett JC, Sfakianos GP, Secord AA, et al. Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer. 2010;10:237.PubMedPubMedCentralCrossRef
61.
go back to reference Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, et al. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. J Clin Oncol. 2019;37(3):178–89.PubMedCrossRef Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, et al. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. J Clin Oncol. 2019;37(3):178–89.PubMedCrossRef
62.
go back to reference Mahadevappa A, Krishna SM, Vimala MG. Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma. J Clin Diagn Res. 2017;11(2):Ec08-ec12.PubMedPubMedCentral Mahadevappa A, Krishna SM, Vimala MG. Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma. J Clin Diagn Res. 2017;11(2):Ec08-ec12.PubMedPubMedCentral
63.
go back to reference Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017;35(10):1061–9.PubMedPubMedCentralCrossRef Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017;35(10):1061–9.PubMedPubMedCentralCrossRef
64.
go back to reference Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, et al. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. Hum Pathol. 2019;85:299–308.PubMedCrossRef Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, et al. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. Hum Pathol. 2019;85:299–308.PubMedCrossRef
65.
go back to reference Chen M, Yao S, Cao Q, Xia M, Liu J, He M. The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients. Oncotarget. 2017;8(64):107877–85.PubMedCrossRef Chen M, Yao S, Cao Q, Xia M, Liu J, He M. The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients. Oncotarget. 2017;8(64):107877–85.PubMedCrossRef
66.
go back to reference Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022;151(9):1535–41.PubMedCrossRef Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022;151(9):1535–41.PubMedCrossRef
Metadata
Title
Relationship between PIWIL1 gene polymorphisms and epithelial ovarian cancer susceptibility among southern Chinese woman: a three-center case–control study
Authors
Shanshan Liu
Yaping Yan
Zhizhong Cui
Haipeng Feng
Fengmei Zhong
Ziguang Liu
Yan Li
Xiang Ou
Wenjuan Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11651-2

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine